RT Journal Article
SR Electronic
T1 SARS-CoV-2 Surveillance in US Wastewater: Leading Indicators and Data Variability Analysis in the 2023-2024 Season
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2024.08.28.24312739
DO 10.1101/2024.08.28.24312739
A1 Schenk, Hannes
A1 Rauch, Wolfgang
A1 Zulli, Alessandro
A1 Boehm, Alexandria B.
YR 2024
UL http://medrxiv.org/content/early/2024/08/28/2024.08.28.24312739.abstract
AB Wastewater-Based Epidemiology (WBE) has become a powerful tool for assessing disease occurrence in communities. This study investigates the coronavirus disease 2019 (COVID-19) epidemic in the United States during the 2023-2024 season using wastewater data from 189 wastewater treatment plants in 40 states and the District of Columbia. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and pepper-mild mottle virus normalized SARS-CoV-2 concentration data were compared with COVID-19 hospitalization admission data at both national and state levels. We further investigate temporal features in wastewater viral abundance, with peak timing and cross-correlation lag analyses indicating that wastewater SARS-CoV-2 concentrations precede hospitalization admissions by 2 to 12 days. Lastly, we demonstrate that wastewater treatment plant size, assessed by number of population served, has a significant effect on the variability of measured SARS-CoV-2 concentrations. This study highlights the effectiveness of WBE as a non-invasive, timely and resource-efficient disease monitoring strategy, especially in the context of declining COVID-19 clinical reporting.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe study was partially supported by the Sergey Brin Family Foundation.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study used only openly available human data that were originally located at https://covid.cdc.gov/covid-data-tracker/#datatracker-homeI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced are available online at https://purl.stanford.edu/hj801ns5929 https://purl.stanford.edu/hj801ns5929